Global Innovative Platforms INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
Global Innovative Platforms Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting initial revenue generation from its VetBreath Dx technology while continuing to incur operating losses.
OID
Global Innovative Platforms reports its first revenue of $136,500 for the six months ended March 31, 2026, while continuing to navigate going concern uncertainties.
OID
Global Innovative Platforms, Inc. reported a significant net loss for Q3 2025 and the nine months ended June 30, 2025, while advancing its pet and agriculture gas outflow diagnostic technology and seeking additional capital.
OID
Global Innovative Platforms reports a net loss of $271,817 for the six months ended March 31, 2025, as it continues to develop its breath analysis technology for animal health.
OID
Global Innovative Platforms reports a net loss for the quarter ended December 31, 2024, and acknowledges substantial doubt about its ability to continue as a going concern.
OID
Global Innovative Platforms, Inc. reports ongoing losses and dependence on external funding, raising concerns about its ability to continue as a going concern.
OID
Global Innovative Platforms reports no revenue and a net loss of $53,355 for the six months ended March 31, 2024, raising substantial doubt about its ability to continue as a going concern.
OID
Global Innovative Platforms Inc. reports a net loss for the quarter ended December 31, 2023, and expresses substantial doubt about its ability to continue as a going concern.